Aldeyra Therapeutics (NASDAQ:ALDX – Get Free Report) is expected to release its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Aldeyra Therapeutics to post earnings of ($0.11) per share and revenue of $2.50 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:00 PM ET.
Aldeyra Therapeutics (NASDAQ:ALDX – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). On average, analysts expect Aldeyra Therapeutics to post ($0.39) EPS for the current fiscal year and ($0.16) EPS for the next fiscal year.
Aldeyra Therapeutics Price Performance
Shares of Aldeyra Therapeutics stock opened at $0.64 on Wednesday. Aldeyra Therapeutics has a 12-month low of $0.60 and a 12-month high of $5.93. The company’s fifty day simple moving average is $1.20 and its two-hundred day simple moving average is $2.36.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on ALDX shares. HC Wainwright reaffirmed a “neutral” rating and set a $2.00 price objective on shares of Aldeyra Therapeutics in a research note on Wednesday, September 30th. BTIG Research reiterated a “buy” rating on shares of Aldeyra Therapeutics in a report on Tuesday, September 29th. Wall Street Zen cut Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings cut Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, September 14th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $5.50.
Read Our Latest Analysis on Aldeyra Therapeutics
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases. The company’s research centers on reactive aldehyde species, or RASP, which are inflammatory signaling molecules that may contribute to ocular and systemic diseases.
Aldeyra’s lead investigational product is reproxalap, an eye drop designed to inhibit RASP activity. The company has studied reproxalap in conditions including dry eye disease and allergic conjunctivitis.
See Also
- Five stocks we like better than Aldeyra Therapeutics
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
